Tenax Therapeutics (TENX) Common Equity: 2011-2017
Historic Common Equity for Tenax Therapeutics (TENX) over the last 4 years, with Sep 2017 value amounting to $10.2 million.
- Tenax Therapeutics' Common Equity fell 78.23% to $10.2 million in Q3 2017 from the same period last year, while for Sep 2017 it was $10.2 million, marking a year-over-year decrease of 78.23%. This contributed to the annual value of $17.1 million for FY2016, which is N/A change from last year.
- As of Q3 2017, Tenax Therapeutics' Common Equity stood at $10.2 million, which was down 9.78% from $11.3 million recorded in Q2 2017.
- In the past 5 years, Tenax Therapeutics' Common Equity registered a high of $82.9 million during Q2 2014, and its lowest value of -$1.8 million during Q2 2013.
- Moreover, its 3-year median value for Common Equity was $31.9 million (2016), whereas its average is $35.1 million.
- Its Common Equity has fluctuated over the past 5 years, first crashed by 413.81% in 2013, then spiked by 4,759.94% in 2014.
- Over the past 5 years, Tenax Therapeutics' Common Equity (Quarterly) stood at -$1.8 million in 2013, then skyrocketed by 4,759.94% to $82.9 million in 2014, then decreased by 15.00% to $60.4 million in 2015, then crashed by 71.63% to $17.1 million in 2016, then plummeted by 78.23% to $10.2 million in 2017.
- Its Common Equity was $10.2 million in Q3 2017, compared to $11.3 million in Q2 2017 and $14.1 million in Q1 2017.